Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma.
Centrosome amplification (CA) as a potential marker of mitotic disruptions in multiple myeloma (MM) was investigated in two populations of B-cell lineage: B-cells and plasma cells (PCs). Using immunofluorescent staining, it was shown that CA in B-cells is present in 3.2+/-2.5% in healthy donors versus 9.9+/-7.9% in MM patients (p<0.0001). Based on the calculated threshold value of CA in B-cells, 37% (14/38) of MM patients were positive. There was no significant correlation between CA-positive MM cases (based on PC samples evaluation) and the occurrence of cytogenetic abnormalities in PCs, including del(13)(q14), del(17)(p13), gain(1)(q21) and hyperdiploidy.
Dementyeva
E
E
University Research Centre, Czech Myeloma Group, Babak Research Institute, Masaryk University, Brno, Czech Republic.
Nemec
P
P
Kryukov
F
F
Muthu Raja
K R
KR
Smetana
J
J
Zaoralova
R
R
Greslikova
H
H
Kupska
R
R
Kuglik
P
P
Hajek
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D018385:Centrosome / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology*; D010950:Plasma Cells / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis